Janux Therapeutics, Inc. (JANX) key performance indicators and operating metrics (4 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Median radiographic progression-free survival, all subjects | 7.30 | FY2025-Q4 |
| Six-month radiographic progression-free survival, all subjects | 51.00 percent | FY2025-Q4 |
| Collaboration revenue | 3.73M | FY2026-Q1 |
| Development milestone payment from Merck | 35M | FY2026-Q1 |
Back to JANX overview · JANX earnings · JANX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.